Adnexus is a leader in the discovery and early development of protein molecules, we call Adnectins. Adnectins are designed to either block or stimulate the action of specific proteins to fight diseases across a broad range of therapeutic areas including oncology and immunology. Our proprietary technology for engineering these proteins creates an opportunity to rapidly generate compounds for further study in a broad range of disease types.

Adnexus is a wholly owned
subsidiary of Bristol-Myers Squibb.